

[54] Title: PARASITICIDES AND INSECTICIDES

[75] Inventor (s): DR. JEAN-CLAUDE GSHRET, of Aesch, Switzerland

[73] Assignee (s): ciba-Geigy AG, of Basle, Switzerland, a Swiss Corporate of Switzerland

[22] Filed: March 25, 1988

[21] Application Serial No: 36686

FOREIGN APPLICATION PRIORITY DATA

[31] Number (s) : 1180/87-0

[32] Date (s) : March 27, 1987

[33] Country (ies) : Switzerland

[52] PH Class 514/450; 549/268


[51] Int. Class C07D 493/22; A01N 43/90

[58] Field of Search C1: 514/450; 549/268

[56] Reference (s) Cited and/or Considered: None

[57]

ABSTRACT




see attached sheet



cont. ABSTRACT

in which



wherein R₁ is hydrogen or an OH-protecting group, and R₁₁ is hydrogen, an OH-protecting group, or an alkyl, cycloalkyl or acyl group,

R₂ is methyl, ethyl, isopropyl, sec.-butyl or a -C(CH₃) = CH - E group wherein E is methyl, ethyl or isopropyl,

R₃ⁱ and R₄ together represent a bond between the two carbon atoms to which they are bonded, or together represent a -C(X')(Z')- group wherein X' and Z' each represents, independently of the other, hydrogen or halogen and

X and Z each represents, independently of the other hydrogen or halogen.

the preparation of the novel compounds and the use thereof for controlling parasites of productive livestock and for controlling harmful insects.


BAD ORIGINAL



PARASITICIDES AND INSECTICIDESABSTRACT

5

A novel compounds of formula



20

In which

A is a $\begin{array}{c} -\text{CH}- \\ | \\ \text{OR}_1 \end{array}$, $\begin{array}{c} -\text{C}- \\ || \\ \text{O} \end{array}$ or $\begin{array}{c} -\text{C}- \\ || \\ \text{N-OR}_{11} \end{array}$ group

wherein R₁ is hydrogen or an OH-protecting group, and
 R₁₁ is hydrogen, an OH-protecting group, or an
 25 alkyl, cycloalkyl or acyl group,

R_2 is methyl, ethyl, isopropyl, sec.-butyl or
a $-C(CH_3) - CH - E$ group wherein E is
methyl, ethyl or isopropyl,

5 R_3 and R_4 together represent a bond between the
two carbon atoms to which they are bonded,
or together represent a $-C(X')(Z')-$ group
wherein X' and Z' each represents, indepen-
dently of the other, hydrogen or halogen
and

10 X and Z each represents, independently of the other,
hydrogen or halogen,

the preparation of the novel compounds and the
use thereof for controlling parasites of productive
livestock and for controlling harmful insects.


15

20


PARASITICIDES AND INSECTICIDES

The present invention relates to milbemycin derivatives of formula I

5



in which



wherein R_1 is hydrogen or an OH-protecting group, and R_{11} is hydrogen, an OH-protecting group, or an alkyl, cycloalkyl or acyl group,

25

R_2 is methyl, ethyl, isopropyl, sec.-butyl
or a $-C(CH_3) = CH - E$ group wherein E is
methyl, ethyl or isopropyl,

5 R_3 and R_4 together represent a bond between the
two carbon atoms to which they are bound,
or together represent a $-C(X')(Z')$ - group
wherein X' and Z' each represents, inde-
pendently of the other, hydrogen or halogen,
and

10 X and Z each represents, independently of the
other, hydrogen or halogen.


The invention also relates to the preparation
of compounds of formula I and to the use thereof
for controlling harmful insects or parasites
15 that infest productive livestock, and to compo-
sitions that contain at least one of these com-
pounds as active ingredient.

Throughout this specification, compounds
in which R_2 is sec.-butyl are also to be regarded
20 as milbemycin derivatives although, according
to conventional classification, they are derived
from avermectin derivatives. Avermectin
aglycons (having an OH group in the 13a - posi-
tion) can, however, be converted into milbemycin

25

homologues in accordance with US-PS
4,173,571.

Naturally occurring milbemycins ($R_1=H$;
 $R_2=CH_3, C_2H_5$ or $iso-C_3H_7$) correspond to formula M
5 given below ($C_{14}-C_{15}$ -double bond):



20

$R_2 = CH_3$	milbemycin A_3 (US-PS 3,950,360)
$R_2 = C_2H_5$	milbemycin A_4 (US-PS 3,950,360)
$R_2 = isoC_3H_7$	milbemycin D (US-PS 4,346,171)
$R_2 = sec.-C_4H_9$	13-deoxy-22,23-dihydro-C-076-B1a- aglycon (US-PS 4,173,571, GB 1,573,955 and DE-OS 2717040).

25


In avermectins, an α - L - oleandrosyl - α -
L - oleandrose radical, which is linked via
the oxygen atom in α - configuration with the
macrolid molecule, is present in the 13-position.

5 Avermectins also differ structurally from mil-
bemycins by a 23-OH group or $\Delta^{22,23}$ -double
bond and usually by a substituent $R_2 = \text{sec.}$
 $-\text{C}_4\text{H}_9$. By hydrolysing the sugar residue of
10 avermectins it is possible easily to obtain
corresponding avermectin aglycons that contain
a 13 α - hydroxy group adjacent to a C = C
double bond. As stated above, avermectin agly-
cons can be converted into milbemycin homologues.
In the milbemycin derivatives of this Application
15 the 22 - C atom and the 23 - C atom together
form the structural moiety $-\text{CH}_2-\text{CH}_2-$ as also
occurs in formula M.

20 The constitution of natural antibiotics
S541 is known from DE - OS 35 32 794 and is
as follows:

25

26026



	Factor A	$E^* = \text{isoC}_3\text{H}_7$	$R_1^* = \text{H}$
	Factor B	$E^* = \text{CH}_3$	$R_1^* = \text{CH}_3$
	Factor C	$E^* = \text{CH}_3$	$R_1^* = \text{H}$
	Factor D	$E^* = \text{C}_2\text{H}_5$	$R_1^* = \text{H}$
5	Factor E	$E^* = \text{CH}_3$	$R_1^* = \text{CH}_3$
	Factor F	$E^* = \text{isoC}_3\text{H}_7$	$R_1^* = \text{CH}_3$

In order to simplify nomenclature, hereinafter the derivatives of antibiotic S541 are classified, according to factor, as derivatives of S541A, S541B, S541C, S541D, S541E or S541F.

26026

Compounds of formula II wherein R_2 is a
-C = CH - E group and E is as defined for
|
CH₃

5 formula II, which can be used as starting ma-
terials in the process of the invention, can be
prepared from the natural antibiotics S541 in
a manner known per se.

The hydroxy group in the 23-position in the
antibiotics S541 can be removed analogously to
10 the method described in US-PS 4,328,335, and the
antibiotics S541 can thus be converted into the
corresponding 23-deoxy derivatives. Those
compounds having a free 5-OH group ($R_1^* = H$)
must first be protected selectively by reaction
15 with one of the silylating reagents $Y - Si(R_6)$
(R_7)(R_8) mentioned below or with tert.-butyl-
dimethylsilyloxyacetyl chloride. The reaction
of these protected compounds in which R_1^* has
been replaced by $Si(R_6)(R_7)(R_8)$ or by $C(=O)$
20 $CH_2OSi - (CH_3)_2$ tert.- C_4H_9 and the 23-C atom
has been substituted by OH, with p-methylphenyl-
chlorothionoformate yields derivatives of the
antibiotics S541 that are substituted at the
23-position by p- $CH_3 - C_6H_4 - O - C(=S) - O -$. These

25

26026

23-0-(4-methylphenoxy)-thiocarbonyl derivatives of antibiotics S541 are then reduced with tributyltin hydride in toluene in the presence of azobisisobutyronitrile at from 80 to 120°C to form the corresponding 23-deoxy derivatives (23-position unsubstituted).

Compounds of formula I wherein R_2 is methyl, ethyl, isopropyl or sec.-butyl are preferred, especially those in which A represents the $-CH(OR_1)-$ and $-C(=N-OR_{11})-$ groups, and R_1 and R_{11} each represents hydrogen.

Throughout this specification, OH-protecting groups for the substituents R_1 and/or R_{11} shall be understood as being the protective functional groups conventionally used in organic chemistry. These are especially acyl and silyl groups. Suitable acyl groups are, for example, $R_5-C(O)-$ radicals wherein R_5 is C_1-C_{10} -alkyl, C_1-C_{10} -haloalkyl, or a representative of the group comprising phenyl and benzyl which is unsubstituted or is substituted by at least one substituent selected from the group comprising halogen, C_1-C_3 -alkyl, C_1-C_3 -haloalkyl, C_1-C_3 -alkoxy, C_1-C_3 -haloalkoxy, cyano and nitro, and

is preferably C_1-C_6 -alkyl, C_1-C_6 -haloalkyl, or phenyl that is unsubstituted or is substituted by halogen, C_1-C_3 -alkyl, CF_3 or by nitro. Suitable silyl groups for the radical R_1 are the $-Si(R_6)(R_7)(R_8)$ radical wherein R_6 , R_7 and R_8 , preferably independently of one another, each represents C_1-C_4 -alkyl, benzyl or phenyl and, for example, together with the silicon atom form any one of the groups trimethylsilyl, diphenyl-tert.-butylsilyl, bis(isopropyl) methylsilyl, triphenylsilyl and, especially, tert.-butyldimethylsilyl. The 5-OH group may also be etherified in the form of the benzyl ether or methoxyethoxy methyl ether or, in accordance with published European Patent No. 185,623, may be bonded to a carbohydrate residue, referred to hereinafter as a sugar residue for the sake of simplicity.

In compounds of formula I in which R_1 is a silyl group, especially tert.-butyldimethylsilyl, or is an acyl group, for example an $R_5-C(=O)-$ group wherein R_5 has the meanings given above and is especially methyl, R_2 , R_3 , R_4 , X and Z are preferably as defined in

25

26026

Tables 1 and 2. In compounds of formula I in which R_{11} is a silyl group, especially tert.-butyldimethylsilyl, or is an acyl group, for example an $R_5-C(O)-$ group wherein R_5 has the meanings given above and is especially methyl, R_2 , R_3 , R_4 , X and Z are preferably as defined in Tables 5 and 6.

Compounds of formula I wherein R_1 and/or R_{11} represent(s) a protecting group can be converted into the highly active free 5-hydroxy derivatives ($R_1 = H$) or 5-hydroxyimino derivatives ($R_{11} = H$) by simple removal of the protecting group, for example by hydrolysis, and thus have also the character of intermediates. The biological value of these compounds is not, however, reduced by the protecting group or the sugar residue.

Depending on the number of carbon atoms indicated, the term "alkyl" as a substituent or as part of a substituent shall be understood as meaning, for example, the following groups: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl or decyl, and the isomers thereof, such as, for example, isopropyl,

26026

isobutyl, tert.-butyl or isopentyl. When R_{11} represents an alkyl group, it contains preferably from 1 to 8, especially from 1 to 4, carbon atoms.

5 Suitable cycloalkyl groups are mono- to tetra-cyclic groups, such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decahydronaphthalene, hydrindane, bicyclopheptane, bicyclooctane, norbornane,
10 bornane or adamantyl. These cycloaliphatic groups are preferably unsubstituted or mono- or poly-substituted by methyl. When R_{11} represents a cycloalkyl group, it contains preferably from 3 to 6 carbon atoms.

15 The above-mentioned acyl and silyl groups serve as protecting groups not only for the hydroxy groups present in the substituent A but also for all other hydroxy groups present in the compounds of the invention or in the
20 precursors of those compounds.

 Halogen in the meaning of X, X', Z and Z' is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine. Halogen atoms bonded to the same
25

26026

carbon atom are preferably identical with one another. Preferred dihalomethylene groups $-C(X)(Z)-$ and $-C(X')(Z')-$ are dichloromethylene and dibromomethylene.

5 The following subgroups of compounds of formula I are preferred on account of their pronounced activity against pests:

Group Ia: compounds of formula I wherein A is
10 any one of the groups $-CH(OR_1)-$, $-C(O)-$ or $-C(=N-OH)-$ wherein R_1 is hydrogen, a silyl group or a monosaccharide group, R_2 is methyl or ethyl, R_3 and R_4 together form a bond between the two carbon atoms to which they are bound, or
15 together form a $\oplus C(X')(Z')-$ group wherein X' and Z' each represents, independently of the other, hydrogen or halogen, and X and Z each represents, independently of the other, hydrogen or halogen;

20 Group Ib: compounds of formula I wherein A is any one of the groups $-CH(OR_1)-$, $-C(O)-$ or $-C(=N-OH)-$ wherein R_1 is hydrogen, acetyl, tert.-butyldimethylsilyl or 2, 3, 4, 6-

25

26026

tetraacetylglucopyranosyl, R_2 is methyl or ethyl, R_3 and R_4 together form a bond between the two carbon atoms to which they are bound, or together form a $-C(Cl_2)-$ group, X is hydrogen, chlorine, bromine or fluorine, and Z is hydrogen, chlorine, bromine or fluorine, X preferably being identical with X in compounds in which X is chlorine, bromine or fluorine;

10 Group Ic: compounds of formula I wherein A is any one of the groups $-CH(OR_1)-$, $-C(O)-$ or $-C(=N-OH)-$ wherein R_1 is hydrogen, tert.-butyldimethylsilyl or 2, 3, 4, 6-tetraacetylglucopyranosyl, R_2 is methyl or ethyl, R_3 and R_4 together form a bond between the two carbon atoms to which they are bound, or together form a $-C(Cl_2)-$ group, X is hydrogen, chlorine or bromine, and Z is hydrogen, chlorine or bromine, Z preferably being identical with X in compounds
15
20 in which X is chlorine or bromine;

Group Id: compounds of formula I wherein A is a $-CH(OH)-$ or $-C(=N-OH)-$ group, R_2 is methyl or ethyl, R_3 and R_4 together form a
25

bond between the two carbon atoms to which they are bound, X is hydrogen, chlorine, bromine or fluorine, and Z is hydrogen, chlorine, bromine or fluorine;

5

Group I e: compounds of formula I wherein A is a $-\text{CH}(\text{OH})-$ or $-\text{C}(=\text{N}-\text{OH})-$ group, R_2 is methyl or ethyl, R_3 and R_4 together form a bond between the two carbon atoms to which they are bound, and X and Z are identical with each other and each represents hydrogen, chlorine, or bromine, or X is hydrogen and Z is chlorine or bromine;

10


Group I f: compounds of formula I wherein A is a $-\text{CH}(\text{OH})-$ group, R_2 is methyl or ethyl, R_3 and R_4 together form a bond between the two carbon atoms to which they are bound, or together form a $-\text{CCl}_2-$ group, X is hydrogen, chlorine or bromine, and Z is hydrogen, chlorine or bromine.

20

Within the scope of this Application,
the structural element

25


26026



is defined by the term "14, 15-dihalomethylene-
14, 15-dihydro";

the structural element

5




10

by the term "14, 15-methylene-14, 15-dihydro";

the structural element

15




20

26026

by the term "14, 15-monohalomethylene-14, 15-dihydro";

the structural element

5




10

by the term "5-oxo";

and the structural element

15



by the term "5-hydroxyimino".

20

The terms used for the optionally halogenated C₃-C₄-methylene group are analogous to those given for C₁₄-C₁₅.

Preferred individual compounds are:

5-O-(tert.-butyldimethylsilyl)-14, 15-dichloromethylene-14, 15-dihydromilbemycin A₄,

25

26026

5-0-(tert.-butyldimethylsilyl)-3, 4-dichloromethylene-14, 15-dichloromethylene-3, 4, 14, 15-tetrahydromilbemycin A₄,

5 3, 4-dichloromethylene-14, 15-dichloromethylene-3, 4, 14, 15-tetrahydromilbemycin A₄,

5-0-(tert.-butyldimethylsilyl)-14, 15-dibromomethylene-14, 15-dihydromilbemycin A₄,

10

5-0-(2, 3, 4, 6-tetraacetylglucopyranosyl)-14, 15-dichloromethylene-14, 15-dihydromilbemycin A₄,

15

5-oxo-14, 15-dichloromethylene-14, 15-dihydromilbemycin A₄,

5-hydroxyimino-14, 15-dichloromethylene-14, 15-dihydromilbemycin A₄,

20

14, 15-dichloromethylene-14, 15-dihydromilbemycin A₃,

5-0-(tert.-butyldimethylsilyl)-14, 15-monobromomethylene-14, 15-dihydromilbemycin A₄,

25

26026

5-0-(tert.-butyldimethylsilyl)-14, 15-methylene-
14, 15-dihydromilbemycin A₄,

14, 15-methylene-14, 15-dihydromilbemycin A₄,

5 and especially

14, 15-dibromomethylene-14, 15-dihydromilbemycin
A₄,

10 14, 15-dichloromethylene-14, 15-dihydromilbemycin
A₄,

14, 15-monobromomethylene-14, 15-dihydromilbemycin
A₄ and

15

14, 15-monochloromethylene-14, 15-dihydromilbe-
mycin A₄.

The preparation of compounds of formula I
can be effected analogously to those methods
described for the addition of carbenes to olefi-
nically unsaturated structures in the literature
relating to carbenes, for example in Liebigs
Ann. Chem. 744, 42-50 (1971) and in Organic
Chemistry, Vol. 1, "Carbene Chemistry", W. Kirmse,

25

26026

in which X and Z are as defined for formula I
and which is formed in situ and is dissolved in
an inert solvent, and, if desired, a resulting
compound of formula I in which R₃ and R₄
5 together form a bond between the carbon atoms
to which they are bound is reacted with a carbene
of formula IIIb



10 in which X' and Z' are as defined for formula I
and which is formed in situ and is dissolved in
an inert solvent. Suitable inert solvents are,
for example, 1, 2-dimethoxyethane, bis(2-methoxy-
15 ethyl) ether, acetonitrile, dichloromethane,
chloroform, dichloroethane and alkanes, such as
pentane or hexane. Temperature and reaction
time are determined to a large extent by the
conditions of the chosen carbene preparation.
20 The temperatures are generally within a range
of from -70°C to +180°C, preferably from 0°C
to 40°C, and the reaction times vary within a
range of approximately from 10 minutes to 2
days. Whereas, at low temperature, compounds

260.26

of formula I in which R_3 and R_4 together form a bond between the two carbon atoms to which they are bound (monoadduct) will preferably be formed, at higher temperatures the proportion of compounds in which R_3 and R_4 together form a $-C(X')(Z')-$ group (diadduct) will predominate.

The manufacture of carbenes of formulae IIIa and IIIb can be effected in conventional manner, such as, for example

- from a mercury salt, such as, for example, phenyl(trifluoromethyl)-mercury at approximately 80°C ;
- from sodium difluorochloroacetate from 100°C to 140°C ;
- from trichloroacetic acid ethyl ester and a base, such as, for example, sodium methoxide at approximately from 0°C to 20°C ;
- from chloroform or bromoform and a base (for example 30-50% aqueous sodium hydroxide solution, potassium tert.-butoxide or butyllithium) with or without phase-transfer catalysts (such as, for example, tetraalkylammonium chlorides or bromides), at temperatures of approximately from

25

26026

-40°C to +60°C, chloroform or bromoform simultaneously serving as solvent (yields dihalocarbenes);

5 - from methylene chloride or methylene bromide and a base (for example 30-50% aqueous sodium hydroxide solution, potassium tert.-butoxide or butyllithium) with or without phase-transfer catalysts (such as, for example, tetraalkylammonium chlorides or bromides), at temperatures
10 of approximately from -40°C to +60°C, it being possible for methylene chloride or methylene bromide to serve simultaneously as solvent (yields monohalocarbenes);

15 - from chloroform, bromoform, methylene chloride or methylene bromide with solid sodium hydroxide or solid potassium hydroxide with exposure to ultrasonic waves.

20 In compounds of formula I it is possible by reduction to convert mono- and di-halomethylene groups into unsubstituted methylene groups or to convert dihalomethylene groups into monohalogenated methylene groups. The reduction can be carried out analogously to known methods, for example using tributyltin hydride or zinc and acid.

26026

Compounds of formula I can be obtained,
for example, either by converting a milbe-
mycin of formula M or the 23-deoxy derivatives
of S541A, S541C or S541D into a compound
5 of formula II in which A has a meaning other
than -CH(OH)- and then reacting with a carbene,
or by first reacting a compound of formula M
or the 23-deoxy derivative of S541A, S541C
or S541D with a carbene and then converting
10 the resulting compound into a compound of for-
mula I in which A has a meaning other than
-CH(OH)-.

It is also possible for substituents at
the 5-C atom in compounds of formulae I and II
15 to be removed and, if desired, replaced by
other substituents provided that these corres-
pond to the definitions according to the in-
vention. The removal and introduction of
substituents corresponding to the definitions
20 according to the invention can be carried out
by methods that are known per se. In order
to introduce acyl, silyl and saccharide groups,
it is advantageous to use as starting materials
compounds of formulae I and II in which A

25

26026

represents $-\text{CH}(\text{OH})-$ or $-\text{C}(=\text{N}-\text{OH})-$,
or compounds of formula M or the 23-deoxy
derivatives of S541A, S541C or S541D. Compounds
of formula I or II in which A represents
5 $-\text{C}(=\text{N}-\text{OR}_{11})-$ can be prepared, for example,
by reacting compounds of formula I or II in
which A represents $-\text{C}(\text{O})-$ with hydroxylamine or
salt thereof and, if desired, subsequently
introducing the substituent R_{11} , which substi-
10 tuent has the meaning given for formula I with
the exception of hydrogen, or by carrying out
the reaction with a compound of formula $\text{NH}_2-\text{OR}_{11}$
or in which R_{11} has the meanings given for
formula I with the exception of hydrogen, or
15 with a salt thereof. Suitable salts are, for
example, those of the above-mentioned amino
compounds with sulphuric acid, nitric acid and,
especially, hydrochloric acid. The reaction
is advantageously carried out in a suitable
20 solvent, for example a lower alkanol, such as
methanol, ethanol, propanol; an ethereal
compound, such as tetrahydrofuran or dioxan; an
aliphatic carboxylic acid, such as acetic acid
or propionic acid; water; or in mixtures of

25

these solvents with each other or with other conventional inert solvents. The reaction temperatures may vary within wide limits.

The reaction is advantageously carried out in the range of approximately from +10° to +100°C. If hydroxylamine is employed in the form of one of its salts, for example in the form of the hydrochloride, in order to bind the acid it is advantageous to add one of the bases customarily used for that purpose and, where appropriate, to carry out the reaction in the presence of a water-binding agent, for example a molecular sieve. Suitable bases are organic and inorganic bases, for example tertiary amines such as trialkylamines (trimethylamine, triethylamine, tripropylamine etc.), pyridine and pyridine bases (4-dimethylaminopyridine, 4-pyrrolidylaminopyridine etc.), oxides, hydrides and hydroxides, carbonates and hydrogen carbonates of alkali metals and alkaline earth metals (CaO, BaO, NaOH, KOH, NaH, Ca(OH)₂, KHCO₃, NaHCO₃, Ca(HCO₃)₂, K₂CO₃, Na₂CO₃), and alkali metal acetates such as CH₃COONa or CH₃COOK. Also suitable are alkali metal alcoholates such

as C_2H_5ONa , $n-C_3H_7ONa$ etc.. Triethylamine is preferred.

Compounds of formulae I and II in which A represents $-C(O)-$ can be obtained, for example, by treating compounds of formula I or II in which A represents $-CH(O)-$ with a reagent suitable for oxidation. Suitable oxidising agents are, for example, activated manganese dioxide, oxalyl chloride/dimethyl sulphoxide/triethylamine or chromium trioxide/pyridine. Another suitable process is the Oppenauer oxidation in which compounds of formulae I and II in which A represents $-CH(O)-$ are reacted with a ketone, preferably cyclohexanone or acetone, in the presence of an aluminium alcoholate, preferably aluminium isopropoxide or aluminium tert.-butoxide.

The oxidation is advantageously carried out in an inert solvent. Suitable solvents are alkanes, such as, for example, hexane, heptane or octane, aromatic hydrocarbons, such as, for example, benzene, toluene or xylenes, or, preferably, chlorinated hydrocarbons, especially methylene chloride. The oxidation is advantageously carried out at temperatures of from

-80°C to +60°C, preferably from -60°C to +30°C.

From compounds of formulae I and II in which A represents a -C(O)- group it is possible, by reduction in a manner known per se, to obtain again compounds in which A represents a -CHOH- group. The reduction can be effected, for example, by catalytic hydrogenation with a platinum or Raney nickel catalyst or in accordance with the Meerwein-Ponndorf-Verley reduction with aluminium isopropoxide in isopropanol,

The introduction of a saccharide into compounds of formula M, into 23-deoxy derivatives of S541A, S541C or S541D or into compounds of formulae I and II in which A represents -CH(OH)- can be effected by reacting these compounds with the corresponding saccharide, advantageously using methods analogous to those generally known in sugar chemistry for linking reactions, such as, for example, the Koenigs-Knorr method, the Ag-triflate process, the so-called orthoester process, the phenylthio synthesis or the 2-pyridylthio method (in accordance with published

26026

European Patent Specification No. 185,623).

For the preparation of compounds of formula II in which R_1 is an acyl group, the 5-OH group of a milbemycin of formula M or of a 23-deoxy derivative of S541A, S541C or S541D is acylated. The introduction of the acyl group is usually carried out using the corresponding acyl halides or acyl anhydrides, the term "acyl halide" meaning acyl chloride or acyl bromide, and is preferably used to introduce the $R_5C(O)-$ group defined at the beginning.

For the preparation of compounds of formula II in which R_1 is a silyl group, the 5-OH group of a milbemycin of formula M or of a 23-deoxy derivative of S541A, S541C or S541D is silylated. For the silylation there is advantageously used a silane of formula $Y-Si(R_6)(R_7)(R_8)$ in which R_6 , R_7 and R_8 have the meanings mentioned hereinbefore and Y represents a silyl leaving group. Silyl leaving groups Y include, for example, bromine, chlorine, cyano, azido, acetamide, trifluoroacetoxy and trifluoromethanesulphonyloxy. This list does not constitute any limitation; the

25

skilled person will know other typical silyl leaving groups.

5 5-O-acylations and 5-O-silylations are carried out in anhydrous medium, preferably in inert solvents and, especially, in aprotic solvents. The reaction proceeds advantageously within a temperature range of from 0° to +80°C, preferably from +10° to +40°C. It is preferably to add an organic base. Suitable organic
10 bases are, for example, tertiary amines such as triethylamine, triethylenediamine, triazole and preferably pyridine, imidazole or 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU).


The removal of these silyl and acyl radicals
15 R_1 or R_{11} in the 5-position is effected by selective mild hydrolysis ($\longrightarrow R_1$ or $R_{11} = H$) for example with dilute acids such as dilute HCl, HF, arylsulphonic acid in alcoholic or aqueous solution, or in accordance with another method
20 familiar to the skilled person. Acyl radicals are preferably removed under basic conditions (for example in alcoholic ammonia solution).

The process of the invention for the preparation of compounds of formula I wherein A,
25

26026

R_2 , R_3 , R_4 , X and Z are as defined for formula I comprises reacting a compound of formula II

5



10

15

in which A and R_2 are as defined for formula I, with a carbene of formula IIIa

20



in which X and Z are as defined for formula I and which is formed in situ and is dissolved in an inert solvent and, in resulting compounds,

25

if desired i) reducing a $-C(\text{halogen})(\text{halogen})-$
 group that represents $-C(X)(Z)-$ to a
 $-CH(\text{halogen})-$ or $-CH_2-$ group or ii) reducing
 a $-CH(\text{halogen})-$ group that represents $-C(X)(Z)-$
 5 to a $-CH_2-$ group or iii) converting the group
 that represents A into another of the groups
 defined under A, or reacting resulting compounds
 in which R_3 and R_4 together form a bond between
 the two carbon atoms to which they are bound
 10 with a carbene of formula IIIb



in which X' and Z' are as defined for formula I
 15 and which is formed in situ and is dissolved
 in an inert solvent, and, in resulting compounds,
 if desired iv) reducing a $-C(\text{halogen})(\text{halogen})-$
 group that represents $-C(X)(Z)-$ or $-C(X')(Z')-$
 to a $-CH(\text{halogen})-$ or $-CH_2-$ group or v)
 20 reducing a $-CH(\text{halogen})-$ group that represents
 $-C(X)(Z)-$ or $-C(X')(Z')-$ to a $-CH_2-$ group
 or vi) converting the group that represents A
 into another of the groups defined under A.

25

26026

The present invention relates also to the described process for the preparation of compounds of formula I.

5 The compounds of formula I are eminently suitable for controlling pests of animals and plants, especially ectoparasites of animals. These last-mentioned pests comprise, of the order Acarina, especially pests of the families Ixodidae, Ermanyssidae, Sarcoptidae and Psoroptidae; the orders Mallophaga, Siphonaptera and Anoplura (for example the Haemotopinidae family); and the order Diptera, especially pests of the families Muscidae, Calliphoridae, Oestridae, Tabanidae, Hippoboscidae and Gastrophilidae.

10 The compounds I can also be used to control hygiene pests, especially of the order Diptera comprising the families Sarcophagidae, Anophilidae and Culicidae; of the order Orthoptera, of the order Dictyoptera (for example the Blattidae family) and of the order Hymenoptera (for example the Formicidae family).

15 The compounds I also have lasting action against mites and insects that are parasites of

25

plants. When used to control spider mites of the order Acarina, they are effective against eggs, nymphs and adults of Tetranychidae (Tetranychus spp. and Panynychus spp.).

5 They have high activity against sucking insects of the order Homoptera, especially against pests of the families Aphididae, Delphacidae, Cicadellidae, Psyllidae, Coccidae, Diaspididae and Eriophididae (for
10 example the rust mite on citrus fruits); of the orders Hemiptera, Heteroptera and Thysanoptera; and against plant-eating insects of the orders Lepidoptera, Coleoptera, Diptera and Orthoptera.

15 They are also suitable as soil insecticides against soil pests.

The compounds of formula I are therefore effective against all developmental stages of sucking and feeding insects in crops such as
20 cereals, cotton, rice, maize, soybeans, potatoes, vegetables, fruits, tobacco, hops, citrus fruit, avocados and others.

The compounds of formula I are also effective against plant nematodes of the species Meloidogyne.

25

Heterodera, Pratylenchus, Ditylenchus,
Radopholus, Rhizoglyphus and others.

The compounds are also effective against
helminths in all developmental stages, and among
5 thee the endoparasitic nematodes can be the
cause of severe diseases in mammals and fowls,
for example sheep, pigs, goats, cattle, horses,
donkeys, dogs, cats, guinea pigs, cage birds.
Typical nematodes having this indication are:

10 Haemonchus, Trichostrongylus, Ostertagia,
Nematodirus, Cooperia, Ascaris, Bunostomum,
Oesophagostomum, Chabertia, Trichuria, Strongylus,
Trichonema, Dictyocaulus, Capillaria, Heterakis,
Toxocara, Ascaridia, Oxyuris, Ancylostoma,
15 Uncinaria, Toxascaris and Parascaris. The
particular advantage of the compounds of formula I
is their activity against parasites that are re-
sistant to benzimidazole-based active substances.

Certain species of the genera Nematodirus,
20 Cooperia and Oesophagostomum attack the intestinal
tract of the host animal, whereas others of the
genera Haemonchus and Ostertagia parasiticise
the stomach and those of the genus Dictyocaulus
the lung tissue. Parasites of the families

25

26026

Filariidae and Setariidae are found in internal cell tissue and in organs, for example in the heart, blood vessels and lymph vessels and in subcutaneous tissue. In this connection, particular mention should be made of the dog heartworm, Dirofilaria immitis. The compounds of formula I are highly effective against these parasites.

The compounds of formula I are also suitable for controlling pathogenic parasites in humans, among which parasites there may be mentioned as typical representatives occurring in the alimentary tract those of the genera Ancylostoma, Necator, Ascaris, Strongyloides, Trichinella, Capillaria, Trichuris and Enterobius. The compounds of this invention are also effective against parasites of the genera Wuchereria, Brugia, Onchocerca and Loa of the Filariidae family, which occur in the blood, in tissue and various organs, and, in addition, against Dracunculus and parasites of the genera Strongyloides and Trichinella which infest in particular the gastro-intestinal tract.

25

26026

The compounds of formula I are used in unmodified form, or preferably together with the adjuvants conventionally employed in the art of formulation, and are therefore formulated in known manner e.g. to emulsifiable concentrates, directly sprayable or dilutable solutions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations in e.g. polymer substances.

As with the nature of the compositions, the methods of application such as spraying, atomising, dusting, scattering or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances.

The compounds of formula I are administered to warm-blooded animals in amounts of from 0.01 to 10 mg/kg of body weight. Over enclosed crop areas they are applied in amounts of from 10 g to 1000 g per hectare. They are also used in pens, paddocks, stalls and other livestock buildings.

The formulations, i.e. the compositions, preparations or mixtures containing the compound (active ingredient) of formula I are prepared

25

26026

in known manner, e.g. by homogeneously mixing
and/or grinding the active ingredients with
extenders, such as, e.g. solvents, solid
carriers and, where appropriate, surface-
5 active compounds (surfactants).

Suitable solvents are: aromatic hydro-
carbons, preferably the fractions containing
8 to 12 carbon atoms, such as, for example,
xylene mixtures or substituted naphthalenes,
10 phthalates, such as dibutyl phthalate or
dioctyl phthalate, aliphatic hydrocarbons, such
as cyclohexane or paraffins, alcohols and glycols
and their ethers and esters, such as ethanol,
ethylene glycol, ethylene glycol monomethyl or
15 monoethyl ether, ketones, such as cyclohexanone,
strongly polar solvents, such as N-methyl-
2-pyrrolidone, dimethyl sulphoxide or dimethyl-
formamide, as well as vegetable oils or epoxidised
vegetable oils, such as epoxidised coconut oil
20 or soybean oil; or water.

The solid carriers used, for example for
dusts and dispersible powders, are normally
natural mineral fillers, such as calcite, talcum,
kaolin, montmorillonite or attapulgite. In order

25

to improve the physical properties it is also possible to add highly dispersed salicylic acid or highly dispersed absorbent polymers.

Suitable granulated adsorptive carriers are porous types, such as, for example, pumice, broken brick, sepiolite or bentonite; and suitable nonsorbent carriers are materials such as calcite or sand. In addition, a great number of pregranulated materials of inorganic or organic nature can be used, such as especially dolomite or pulverised plant residues.

Depending on the nature of the active ingredient to be formulated, suitable surface-active compounds are nonionic, cationic and/or anionic surfactants having good emulsifying, dispersing and wetting properties. The term "surfactants" will also be understood as including mixtures of surfactants.

Both so-called water-soluble soaps and water-soluble synthetic surface-active compounds are suitable anionic surfactants.

Suitable soaps are the alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammonium salts of higher fatty acids

(C₁₀-C₂₂), such as, for example, the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures which can be obtained, for example, from coconut oil or tallow oil. Other suitable surfactants are also the fatty acid methyltaurin salts.

More frequently, however, so-called synthetic surfactants are used, especially fatty sulphonates, fatty sulphates, sulphonated benzimidazole derivatives or alkylarylsulphonates.

The fatty sulphonates or sulphates are usually in the form of alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammonium salts and contain a C₈-C₂₂-alkyl radical, alkyl also including the alkyl moiety of acyl radicals, for example the sodium or calcium salt of lignosulphonic acid, of dodecylsulphate or of a mixture of fatty alcohol sulphates obtained from natural fatty acids. These compounds also comprise the salts of the sulphuric acid esters and sulphonic acids of fatty alcohol/ethylene oxide adducts. The sulphonated benzimidazole derivatives preferably contain 2 sulphonic acid groups and

26026

one fatty acid radical containing 8 to 22 carbon atoms. Examples of alkylarylsulphonates are the sodium, calcium or triethanolamine salts of dodecylbenzenesulphonic acid, dibutyl-naphthalenesulphonic acid, or of a condensate of naphthalenesulphonic acid and formaldehyde.

Also suitable are corresponding phosphates, such as, for example, salts of the phosphoric acid ester of an adduct of *p*-nonylphenol with 4 to 14 moles of ethylene oxide; or phospholipids.

Non-ionic surfactants are especially polyglycol ether derivatives of aliphatic or cycloaliphatic alcohols, saturated or unsaturated fatty acids and alkylphenols, said derivatives containing 3 to 30 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic)hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenols.

Further suitable non-ionic surfactants are the water-soluble adducts of polyethylene oxide with polypropylene glycol, ethylenediaminopolypropylene glycol and alkylpolypropylene glycol containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethylene

26026

glycol ether groups and 10 to 100 propylene glycol ether groups. These compounds usually contain 1 to 5 ethylene glycol units per propylene glycol unit.

5 Representative examples of non-ionic surfactants are nonylphenolpolyethoxyethanols, castor oil polyglycol ethers, polypropylene/polyethylene oxide adducts, tributylphenoxy-polyethoxyethanol, polyethylene glycol and
10 octylphenoxypolyethoxyethanol.

 Fatty acid esters of polyoxyethylene sorbitan, e.g. polyoxyethylene sorbitan trioleate, are also suitable non-ionic surfactants.

 Cationic surfactants are especially
15 quaternary ammonium salts which contain, as N-substituent, at least one C_8-C_{22} -alkyl radical and, as further substituents, unsubstituted or halogenated lower alkyl, benzyl or hydroxy-lower alkyl radicals. The salts are preferably
20 in the form of halides, methyl sulphates or ethyl sulphates, e.g. stearyltrimethylammonium chloride or benzyldi-(2-chloroethyl)ethylammonium bromide.

 The surfactants customarily employed in the
25

260 26

art of formulation are described inter alia
in the following publication:

"1986 International McCutcheon's Emulsifiers
and Detergents", The Manufacturing Confectioner
Publishing Co., Glen Rock, New Jersey, USA.

The pesticidal compositions usually contain
from 0.01 to 95 %, especially from 0.1 to
80 %, of an active ingredient of formula I,
from 5 to 99.99 % of a solid or liquid adjuvant,
and from 0 to 25 %, especially from 0.1 to
25 %, of a surfactant.

Whereas commercial products are preferably
formulated as concentrates, the end user will
normally employ dilute formulations having an
active ingredient content of from 1 to 10,000 ppm.

The present invention therefore also relates
to pesticidal compositions which contain as
active ingredient at least one compound of
formula I together with customary carriers and/or
dispersing agents.

The compositions may also contain further
ingredients such as stabilisers, antifoams,
viscosity regulators, binders, tackifiers and
also fertilisers or other active ingredients

for obtaining special effects.

Preparation Examples

5 Example P-1: Preparation of 5-O-(tert.-
butyldimethylsilyl)-14, 15-dichloromethylene-
14, 15-dihydromilbemycin A_4 and 5-O-(tert.-
butyldimethylsilyl)-3, 4-dichloromethylene-
14, 15-dichloromethylene-3, 4, 14, 15-tetra-
10 hydromilbemycin A_4

10

With continuous stirring at from 0 to
5°C, 15 ml of a 50% aqueous sodium hydroxide
solution are added to a solution of 1300 mg of
15 5-O-(tert.-butyldimethylsilyl)-milbemycin A_4
and 15 mg of tetrabutylammonium chloride in 60
ml of chloroform. After 30 minutes, the reac-
tion mixture is diluted with 200 ml of ethyl
acetate and washed until neutral with water/sodium
20 chloride solution. After drying the solution
over sodium sulphate and concentrating by evapor-
ation, the residue is purified over silica gel
(hexane : ether = 5:1). Freeze-drying of the
product yields 1090 mg of 5-O-(tert.-butyldimethyl-

25

26026

silyl)-14, 15-dichloromethylene-14, 15-dihydromilbemycin A_4 , m.p. 102-105°C, and 80 mg of 5-O-(tert.-butyldimethylsilyl)-3, 4-dichloromethylene-14, 15-dichloromethylene-3, 4, 14, 15-tetrahydromilbemycin A_4 , m.p. approximately 200°C.

By removing the silyl group from 5-O-(tert.-butyldimethylsilyl)-3, 4-dichloromethylene-14, 15-dichloromethylene-3, 4, 14, 15-tetrahydromilbemycin A_4 , 3, 4-dichloromethylene-14, 15-dichloromethylene-3, 4, 14, 15-tetrahydromilbemycin A_4 , m.p. 153-157°C. is obtained.

Example P-2: Preparation of 14, 15-dichloromethylene-14, 15-dihydromilbemycin A_4

120 mg of 5-O-(tert.-butyldimethylsilyl)-14, 15-dichloromethylene-14, 15-dihydromilbemycin A_4 in 5 ml of a 1% methanolic solution of *p*-toluenesulphonic acid are stirred at room temperature for one hour and then treated with 5% aqueous sodium hydrogen carbonate solution. After extracting by shaking three times with

25

26026

20 ml of diethyl ether each time, drying over sodium sulphate, concentrating the organic phase and chromatographing the crude product on 20 g of silica gel (eluant: diethyl ether), 92 mg
5 of 14, 15-dichloromethylene-14, 15-dihydromilbemycin A_4 are obtained; m.p. 127-131°C.

By reacting 14, 15-dichloromethylene-14, 15-dihydromilbemycin A_4 with 2, 3, 4, 6-tetraacetylglucopyranose, 5-O-(2, 3, 4, 6-tetraacetylglucopyranosyl)-14, 15-dichloromethylene-14, 15-dihydromilbemycin A_4 , m.p. 133-138°C (compound
10 No. 7.1) is obtained.

Example P-3: Preparation of 14, 15-dichloromethylene-
15 14, 15-dihydromilbemycin A_3

With continuous stirring at from 0 to 3°C, 7 ml of a 50% aqueous sodium hydroxide solution
20 are added to a solution of 400 mg (0.75 mmol) of milbemycin A_3 and 5 mg of tetrabutylammonium chloride in 50 ml of chloroform. After 15 minutes, the reaction mixture is diluted with 100 ml of diethyl ether and washed with water/sodium

25

26026

chloride solution until a neutral reaction is
obtained. The solution is dried over sodium
sulphate and concentrated by evaporation. The
resulting residue is purified over a silica
5 column (hexane : ether = 4:1). Freeze-drying
of the resulting product yields 212 mg of
14, 15-dichloromethylene- 14, 15-dihydromilbemycin
A₃; m.p. 130-135°C.

10 Example P-4: Preparation of 14, 15-dibromo-
methylene-14, 15-dihydromilbemycin A₄

0.5 ml of bromoform is added at room tem-
15 perature to 100 mg of milbemycin A₄ and
100 mg of magnesium shippings in 5 ml of
diethyl ether. The reaction mixture, in which
an exothermic reaction commences after a few
minutes, is maintained at from 30 to 35°C by
20 cooling with an ice bath until, after about one
hour, the reaction is complete. The reaction
mixture is filtered and concentrated. Puri-
fication of the crude product by column
chromatography (silica gel; diethyl ether/
25

26026

hexane = 10:1) yields 78 mg of 14, 15-dibromo-methyl-methylene-14, 15-dihydromilbemycin A_4 which decomposes at 141 - 144°C.

5 By introducing the $-Si(CH_3)_2$ -tert.- C_4H_9 group into 14, 15-dibromomethylene-14, 15-dihydromilbemycin A_4 , 5-O-(tert.-butyldimethylsilyl)-14, 15-dibromomethylene-14, 15-dihydromilbemycin A_4 , m.p. 137-141°C, is obtained.

10 Example P-5: Preparation of 5-O-(tert.-butyldimethylsilyl)-14, 15-dichloromethylene-14, 15-dihydromilbemycin A_4

15 1 ml of n-butyllithium is added dropwise at $-60^\circ C$, under argon, to 100 mg of 5-O-(tert.-butyldimethylsilyl)-milbemycin A_4 in 4 ml of dry chloroform. The reaction mixture is slowly heated to $20^\circ C$, stirred thoroughly for
20 4 hours and then filtered and concentrated. The resulting crude product is purified by column chromatography (silica gel; diethyl ether/petroleum ether = 1:5). 90 mg of 5-O-(tert.-butyldimethylsilyl)-14, 15-dichloromethylene-

25

26026

14, 15-dihydromilbemycin A_4 , m.p. 103-105°C,
are obtained.

5 Example P-6: Preparation of 5-O-(tert.-butyl-
dimethylsilyl)-14, 15-monobromomethylene-14,
15-dihydromilbemycin A_4 and 5-O-(tert.-butyl-
dimethylsilyl)-14, 15-methylene-14, 15-dihydro-
milbemycin A_4

10 2.0 g of zinc powder are slowly added at
15°C to a solution of 200 mg (0.24 mmol) of
5-O-(tert.-butyldimethylsilyl)-14, 15-dibromo-
methylene-14, 15-dihydromilbemycin A_4 in 10 ml
15 of glacial acetic acid. After 4 hours, the
solvent is evaporated off in vacuo and the
residue is filtered and purified over a silica
gel column (cyclohexane : ethyl acetate = 12:1).
Freeze-drying yields 70 mg of 5-O-(tert.-butyl-
20 dimethylsilyl)-14, 15-monobromomethylene-14,
15-dihydromilbemycin A_4 in the form of an
amorphous powder, m.p. 180-185°C, and 100
mg of 5-O-(tert.-butyldimethylsilyl)-14, 15-
25 methylene-14, 15-dihydromilbemycin A_4 in

26026

amorphous form, which melts at approximately 75°C.

5 Example P-7: Preparation of 14, 15-monobromomethylene-14, 15-dihydromilbemycin A₄

10 2 ml of 1% methanolic p-toluenesulphonic acid solution is added at room temperature to 70 mg of 5-O-(tert.-butyldimethylsilyl)-14, 15-monobromomethylene-14, 15-dihydromilbemycin A₄. Working up in accordance with the foregoing Examples yields 14, 15-monobromomethylene-14, 15-dihydromilbemycin A₄ in the form of an amorphous powder which melts at 85-88°C.

15

Example P-8: Preparation of 14, 15-methelene-14, 15-dihydromilbemycin A₄

20 2 ml of 1% methanolic p-toluenesulphonic acid solution is added at room temperature to 100 mg of 5-O-(tert.-butyldimethylsilyl)-14, 15-methylene-14, 15-dihydromilbemycin A₄.

25

26026

Working up in accordance with the foregoing Examples yields 14, 15-methylene-14, 15-dihydromilbemycin A₄ in the form of an amorphous powder which melts at 80-83°C.


5 14, 15-dichloromethylene-14, 15-dihydromilbemycin A₄ can be oxidised to 5-oxo-14, 15-dichloromethylene-14, 15-dihydromilbemycin A₄ and, by reaction of this 5-oxo compound with hydroxylamine, it is possible to prepare 5-
10 hydroxyimino-14, 15-dichloro-14, 15-dihydromilbemycin A₄; m.p. 171-173°C.

 The following compounds of formula I, listed together with compounds of the preceding Examples, are also prepared analogously to the described
15 procedures. this list does not, however, constitute any limitation.

20

25

Table 1



15

Comp.

No.	R ₂	X	Z
1.1	CH ₃	H	Br
1.2	C ₂ H ₅	H	Br
20 1.3	C ₃ H ₇ -iso	H	Br
1.4	C ₄ H ₉ -sec.	H	Br
1.5	CH ₃	H	Cl
1.6	C ₂ H ₅	H	Cl
1.7	C ₃ H ₇ -iso	H	Cl

25

Table 1 (continued)

Comp. No.	R ₂	X	Z	
5	1.8	C ₄ H ₉ -sec.	H	Cl
	1.9	CH ₃	H	H
	1.10	C ₂ H ₅	H	H
10	1.11	C ₃ H ₇ -iso	H	H
	1.12	C ₄ H ₉ -sec.	H	H
	1.13	CH ₃	Cl	Cl
	1.14	C ₂ H ₅	Cl	Cl
	1.15	C ₃ H ₇ -iso	Cl	Cl
15	1.16	C ₄ H ₉ -sec.	Cl	Cl
	1.17	CH ₃	Br	Br
	1.18	C ₂ H ₅	Br	Br
	1.19	C ₃ H ₇ -iso	Br	Br
	1.20	C ₄ H ₉ -sec.	Br	Br
20	1.21	CH ₃	H	F
	1.22	C ₂ H ₅	I	I
	1.23	C ₃ H ₇ -iso	Cl	Br
	1.24	C ₄ H ₉ -sec.	H	I
	1.25	CH ₃	Cl	Br
25	1.26	C ₂ H ₅	F	F

Table 1 (continued)

26026

	Comp. No.	R ₂	X	Z
5	1.27	C ₃ H ₇ -iso	H	F
	1.28	C ₄ H ₉ -sec.	Cl	I
	1.29	CH ₃	F	F
	1.30	C ₂ H ₅	Cl	Br
10	1.31	C ₃ H ₇ -iso	Br	F
	1.32	C ₄ H ₉ -sec.	H	F
	1.33	CH ₃	Br	I
	1.34	C ₂ H ₅	H	F
	1.35	C ₃ H ₇ -iso	F	F
15	1.36	C ₄ H ₉ -sec.	Cl	Br
	1.37	CH ₃	F	I
	1.38	C ₂ H ₅	H	I
	1.39	C ₃ H ₇ -iso	Cl	I
	1.40	C ₄ H ₉ -sec.	Br	F
20	1.41	CH ₃	H	I
	1.42	C ₂ H ₅	Cl	F
	1.43	C ₃ H ₇ -iso	Br	I
	1.44	C ₄ H ₉ -sec.	I	I
	1.45	CH ₃	Br	F

25

Table 1 (continued)

Comp.	R ₂	X	Z	
5	1.46	C ₂ H ₅	Cl	I
	1.47	C ₃ H ₇ -iso	H	I
	1.48	C ₄ H ₉ -sec.	F	F
	1.49	CH ₃	Cl	I
10	1.50	C ₂ H ₅	Br	F
	1.51	C ₃ H ₇ -iso	Cl	F
	1.52	C ₄ H ₉ -sec.	Br	I
	1.53	CH ₃	I	I
	1.54	C ₂ H ₅	Br	F
15	1.55	C ₃ H ₇ -iso	F	I
	1.56	C ₄ H ₉ -sec.	F	I
	1.57	CH ₃	Cl	F
	1.58	C ₂ H ₅	F	I
	1.59	C ₃ H ₇ -iso	I	I
20	1.60	C ₄ H ₉ -sec.	Cl	F

and the compounds of Table 1 in which the hydrogen atom of the hydroxy group in the 5-position has been

26026

replaced by a silyl group $-\text{Si}(\text{CH}_3)_2\text{-tert.-}$
 C_4H_9 (= compounds S-1.1 to S 1.60) and the
compounds of Table 1 in which the hydrogen atom
of the hydroxy group in the 5-position has been
5 replaced by the acyl group $-\text{COCH}_3$ (= compounds
A-1.1 to A-1.60).

10

15

20

25


26026

Table 2:

5

10

15



Comp. No.	R ₂	X	Z	X'	Z'
2.1	CH ₃	H	Br	H	Br
2.2	C ₂ H ₅	H	Br	H	Br
2.3	C ₃ H ₇ -iso	H	Br	H	Cl
2.4	C ₄ H ₉ -sec.	H	Br	H	Cl
2.5	CH ₃	H	Cl	H	H

25

Table 2 (continued)

Comp. No.	R ₂	X	Z	X'	Z'
5					
2.6	C ₂ H ₅	H	Cl	H	Cl
2.7	C ₃ H ₇ -iso	H	Cl	H	H
2.8	C ₄ H ₉ -seC.	H	Cl	H	Br
10	2.9	CH ₃	H	H	H
2.10	C ₂ H ₅	H	H	Cl	Cl
2.11	C ₃ H ₇ -iso	H	H	Br	Br
2.12	C ₄ H ₉ -seC.	H	H	H	H
2.13	CH ₃	Cl	Cl	Cl	Cl
15	2.14	C ₂ H ₅	Cl	Cl	Cl
2.15	C ₃ H ₇ -iso	Cl	Cl	Br	Br
2.16	C ₄ H ₉ -seC.	Cl	Cl	I	I
2.17	CH ₃	Br	Br	H	H
2.18	C ₂ H ₅	Br	Br	Br	Br
20	2.19	C ₃ H ₇ -iso	Br	Br	Br
2.20	C ₄ H ₉ -seC.	Br	Br	H	H
2.21	CH ₃	H	F	H	F
2.22	C ₂ H ₅	I	I	I	I
2.23	C ₃ H ₇ -iso	Cl	Br	Cl	Cl

25

Table 2 (continued)

Comp. No.	R ₂	X	Z	X'	Z'	
5						
2.24	CH ₃	Cl	Br	Cl	Br	
2.25	C ₂ H ₅	F	F	F	F	
2.26	CH ₃	F	F	Cl	Cl	
10	2.27	C ₂ H ₅	Cl	Br	Cl	Br
2.28	C ₄ H ₉ -seC.	H	F	H	H	
2.29	C ₂ H ₅	H	F	H	F	
2.30	C ₃ H ₇ -iso	F	F	F	F	
2.31	C ₄ H ₉ -seC.	Cl	Br	Cl	Cl	
15	2.32	C ₂ H ₅	H	I	H	Cl
2.33	CH ₃	H	I	H	I	
2.34	C ₂ H ₅	Cl	F	Cl	F	
2.35	CH ₃	I	I	Cl	Cl	
2.36	CH ₃	Cl	F	Cl	Br	
20	2.37	C ₂ H ₅	F	I	H	H

25

26026

and the compounds of Table 2 in which the hydrogen atom of the hydroxy group in the 5-position has been replaced by the silyl group $-\text{Si}(\text{CH}_3)_2\text{-tert.-C}_4\text{H}_9$ (= compounds S-2.1 to S-2.37) and the compounds of Table 2 in which the hydrogen atom of the hydroxy group in the 5-position has been replaced by the acyl group $-\text{COCH}_3$ (= compounds A-2.1 to A-2.37).

5


10

15

20

25

Table 3:



15

Comp. No.	R ₂	X	Z
20 3.1	CH ₃	H	H
3.2	C ₂ H ₅	H	H
3.3.	C ₃ H ₇ -iso	H	H
3.4	C ₄ H ₉ -sec.	H	H
3.5	CH ₃	Br	Br

25




Table 3 (continued)

26026

	Comp. No.	R ₂	X	Z
5	3.6	C ₂ H ₅	Br	Br
	3.7	C ₃ H ₇ -iso	Br	Br
	3.8	C ₄ H ₉ -seC.	Br	Br
	3.9	CH ₃	Cl	Cl
10	3.10	C ₂ H ₅	Cl	Cl
	3.11	C ₃ H ₇ -iso	Cl	Cl
	3.12	C ₄ H ₉ -seC	Cl	Cl
	3.13	CH ₃	H	Br
	3.14	C ₂ H ₅	H	Br
15	3.15	C ₃ H ₇ -iso	H	Br
	3.16	C ₄ H ₉ -seC.	H	Br
	3.17	CH ₃	H	Cl
	3.18	C ₂ H ₅	H	Cl
	3.19	C ₃ H ₇ -iso	H	Cl
20	3.20	C ₄ H ₉ -seC.	H	Cl
	3.21	CH ₃	H	F
	3.22	C ₂ H ₅	H	F
	3.23	C ₃ H ₇ -iso	H	F
	3.24	C ₄ H ₉ -seC.	H	F
25				

Table 4:

26026



15

Comp. No.	R ₂	X	Z	X'	Z'
20 4.1	C ₃ H ₇ -iso	Cl	Cl	Br	Br
4.2	CH ₃	Br	Br	Cl	Cl
4.3	C ₂ H ₅	H	Br	H	Br

25

Table 4 (continued)


Comp. No.	R ₂	X	Z	X'	Z'	
5						
4.4.	CH ₃	H	H	H	H	
4.5	C ₄ H ₉ -seC.	Br	Br	H	H	
4.6	CH ₃	H	Br	H	Cl	
10	4.7	C ₃ H ₇ -iso	H	H	H	H
4.8	C ₂ H ₅	Cl	Cl	Cl	Cl	
4.9	C ₄ H ₉ -seC.	Cl	Cl	H	H	
4.10	C ₂ H ₅	H	H	Cl	Cl	
4.11	C ₂ H ₅	Br	Br	Br	Br	
15	4.12	CH ₃	Cl	Cl	Cl	Cl

20

25

Table 5:

26026



Comp. No.	R ₂	X	Z
-----------	----------------	---	---

20

5.1	CH ₃	H	H
5.2	C ₂ H ₅	H	H
5.3	C ₃ H ₇ -iso	H	H
5.4	C ₄ H ₉ -sec.	H	H
5.5.	CH ₃	Br	Br

25

Table 5 (continued):

Comp. No.	R ₂	X	Z
5			
5.6	C ₂ H ₅	Br	Br
5.7	C ₃ H ₇ -iso	Br	Br
5.8	C ₄ H ₉ -secC.	Br	Br
5.9	CH ₃	Cl	Cl
10			
5.10	C ₂ H ₅	Cl	Cl
5.11	C ₃ H ₇ -ido	Cl	Cl
5.12	C ₄ H ₉ -secC	Cl	Cl
5.13	CH ₃	H	Br
5.14	C ₂ H ₅	H	Br
15			
5.15	C ₃ H ₇ -iso	H	Br
5.16	C ₄ H ₉ -secC.	H	Br
5.17	CH ₃	H	Cl
5.18	C ₂ H ₅	H	Cl
5.19	C ₃ -H ₇ -iso	H	Cl
20			
5.20	C ₄ H ₉ -secC	H	Cl
5.21	CH ₃	H	F
5.22	C ₂ H ₅	H	F
5.23	C ₃ H ₇ -iso	H	F
5.24	C ₄ H ₉ -secC.	H	F
25			

and the compounds of Table 5 in which the hydrogen atom of the oxime group in the 5-position has been replaced by the silyl group $-\text{Si}(\text{CH}_3)_2\text{-tert.-C}_4\text{H}_9$ (= compounds S-5.1 to S-5.24) and the compounds of Table 5 in which the hydrogen atom of the oxime group in the 5-position has been replaced by the acyl group $-\text{COCH}_3$ (= compounds A-5.1 to A-5.24).

5

10


15

20

25

26026

Table 6:



Comp. No.	R ₂	X	Z	X'	Z'
6.1	CH ₃	Cl	Cl	Cl	Cl
6.2	C ₂ H ₅	Br	Br	Br	Br
6.3	C ₂ H ₅	H	H	H	H
6.4	C ₄ H ₉ -sec.	Cl	Cl	H	H
6.5	C ₂ H ₅	Cl	Cl	Cl	Cl



Table 6 (continued):

Comp. No.	R ₂	X	Z	X'	Z'	
5						
6.6.	C ₃ H ₇ -iso	H	H	Br	Br	
6.7	CH ₃	H	Br	H	Br	
6.8	C ₄ H ₉ -sec.	Br	Br	Cl	Cl	
10	6.9	CH ₃	H	H	Cl	
6.10	C ₂ H ₅	H	Br	H	Br	
6.11	CH ₃	Br	Br	H	H	
6.12	C ₃ H ₇ -iso	Cl	Cl	Br	Br	
6.13	C ₂ H ₅	Cl	Br	Br	Cl	
15	6.14	C ₄ H ₉ -sec.	Br	Cl	Br	Cl

and the compounds of Table 6 in which the hydrogen atom of the oxime group in the 5-position has been replaced by the silyl group -Si(CH₃)₂-tert.-C₄H₉ (= compounds S-6.1 to S-6.14) and the compounds of Table 6 in which the hydrogen atom of the oxime group in the 5-position has been replaced by the acyl group -COCH₃ (= compounds A-6.1 to A-6.14).

26026

Formulation Examples for the active ingredients
of formula 1

(% = per cent by weight)

5	<u>Wettable powders</u>	a)	b)	c)
	an active ingredient			
	from Tables 1 to 6	25%	50%	75%
	sodium lignosulphonate	5%	5%	-
10	sodium laurylsulphate	3%	-	5%
	sodium diisobutyl-naphthalenesulphonate	-	6%	10%
15	octylphenol polyethylene glycol ether (7-8 moles of ethylene oxide)	-	2%	-
20	highly dispersed silicic acid	5%	10%	10%
	kaolin	62%	27%	-
25				

26026

The active ingredient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill. Wettable powders are obtained which can be diluted with water to give suspensions of any desired concentration.

	<u>Emulsifiable concentrate</u>	
	an active ingredient	
10	from Tables 1 to 6	10%
	octylphenol polyethylene glycol ether (4-5 moles of ethylene oxide)	3%
15	calcium dodecylbenzene-sulphonate	3%
	castor oil polyglycol ether (36 moles of ethylene oxide)	4%
20	cyclohexanone	30%
	xylene mixture	50%

25

26026

Emulsions of any desired concentration can be prepared from this concentrate by dilution with water.

5	<u>Dusts</u>	a)	b)
	an active ingredient		
	from Tables 1 to 6	5%	8%
10	talcum	95%	-
	kaolin	-	92%

Ready-for-use dusts are obtained by mixing the active ingredient with the carrier and grinding the mixture in a suitable mill.

	<u>Extruder granulate</u>		
	an active ingredient from		
20	Tables 1 to 6		10%
	Sodium lignosulphonate		2%
	Carboxymethylcellulose		1%
	kaolin		87%

25

26026

The active ingredient is mixed and ground with the adjuvants, and the mixture is moistened with water. This mixture is extruded and then dried in a stream of air.

5

Tablets or boli

I	an active ingredient	
	from Tables 1 to 6	33.00%
10		
	methylcellulose	0.80%
	highly dispersed	
	silicic acid	0.80%
15		
	maizemaize starch	8.40%

20

25

The methylcellulose is stirred in water and allowed to swell; silicic acid is stirred in to give a homogeneous suspension. The active ingredient and the maize starch are mixed and the aqueous suspension is incorporated into this mixture, which is kneaded to a paste. This mass is granulated through a sieve (mesh width 12 M) and the granulate is then dried.

26026

II	crystalline lactose	22.50%
	maize starch	17.00%
5	microcrystalline cellulose	16.50%
	magnesium stearate	1.00%

All 4 adjuvants are thoroughly mixed.
10 Phases I and II are mixed and compressed to
form tablets or boli.

Injectable composition

A. Oily vehicle (slow release)

15	an active ingredient from the Tablets	0.1-1.0g
	groundnut oil	ad 100 ml
20	an active ingredient from the Tablets	0.1-1.0 g
	sesame oil	ad 100 ml

25

26026

Preparation: The active ingredient is dissolved in some of the oil while stirring, and, if necessary, while heating gently; after cooling, the solution is made up to prescribed volume and sterile-
5 filtered through a suitable membrane filter having a pore diameter of 0.22 μ m.

B. Water-miscible solvent (medium rate of release)

10	an active ingredient	
	from the Tables	0.1-1.0 g
	4-hydroxymethyl-1,3-	
	dioxolane (glycerol formal)	40.0 g
15	1,2-propanediol	ad 100 ml
	an active ingredient	
	from the Tables	0.1-1.0 g
20	glycerin dimethyl ketal	40.0 g
	1,2-propanediol	ad 100 ml

25

26026

Preparation: the active ingredient is dissolved
in some of the solvent while stirring, and the
solution is made up to the prescribed volume and
sterile-filtered through a suitable membrane filter
5 having a pore diameter of 0.22 μ m.

C. Aqueous solubilisate (rapid release)

10	an active ingredient from the Tables	0.1-1.0 g
	polyethoxylated castor oil (40 ethylene oxide units)*	10 g
15	1,2-propanediol	20 g
	benzyl alcohol	1 g
	aqua ad inject.	ad 100 ml

20

*Available commercially under the name
CREMOPHOR^(R) EL (BASF AG);

25

26026

an active ingredient

from the Tables

0.1-1.0 g

5

polyethoxylated sorbitan
monooleate (20 ethylene
oxide units)**

8 g

10

4-hydroxymethyl-1,3-dioxolane
(glycerol formal)

20 g

benzyl alcohol

1 g

aqua ad inject.

ad 100 ml

15

**Available commercially under the name
TWEEN^(R) 80 (ICI);

20

Preparation: the active ingredient is dissolved
in the solvents and the surfactant and the
solution is made up to prescribed volume with
water. Sterile-filtration is carried out through
a suitable membrane filter having a pore diameter
of 0.22 μ m.

25

260.26

The aqueous systems can preferably also be used for oral and/or intraruminal administration.

When compounds of formula I or corresponding compositions are used for controlling endoparasitic nematodes, cestodes and trematodes in domestic animals and productive livestock, such as cattle, sheep, goats, cats and dogs, the compounds or compositions can be administered to the animal either as a single dose or repeatedly, the individual doses preferably being from 0.1 to 10 mg per kg of body weight depending on the type of animal. By protracted administration it is possible in some cases to achieve a better action of lower overall doses can suffice. The active ingredient, or the composition containing it, can also be added to the feed or the drink. The concentration of active ingredient in the prepared feed is preferably from 0.005 to 0.1 % by weight. The compositions can be administered to the animals perorally in the form of solutions, emulsions, suspension, powders, tablets, boli or capsules. Provided that the physical and toxicological properties of solutions or emulsions permit, the compounds

25

26026

of formula I, or the compositions containing them, can also be administered to the animal, for example, by subcutaneous injection or intraruminally, or can be applied to the body of the animal by means of the pour-on method. It is also possible to administer the active ingredient to the animal by means of licks (salt) or molasses blocks.

10 Biological Examples

B-1: Action against L₁ larvae of *Lucilia sericata*

15 1 ml of an aqueous suspension of the active substance to be tested is mixed in such a manner with 3 ml of a special larval culture medium at about 50°C that a homogeneous composition containing, as desired, 250 ppm or 125 ppm of active ingredient is obtained. About 30
20 *Lucilia* larvae (L₁) are put into each test tube containing active ingredient. The mortality rate is ascertained after 4 days. Compounds from the Preparation Examples, such as for example, compounds Nos. 1.14, 1.18, 5.5 and
25

26026

7.1 (compound from Example p-2), achieve
100 % effectiveness at 100 ppm.

5 These results are also obtained in the
same test against L₁ larvae of Lucilia
cuprina.

B-2: Acaricidal action against Boophilus microplus (Biarra strain)

10 Adhesive tape is so applied horizontally
across a PVC plate that 10 female Boophilus
microplus ticks (Biarra strain) fully replete
with blood can be affixed thereto on their backs,
side by side, in a row. Each tick is injected
15 from an injection needle with 1 ul of a liquid
which is a 1:1 mixture of polyethyleneglycol
and acetone, in which mixture a specific amount
of active ingredient of, as desired, 1, 0.1
or 0.01 ul per tick is dissolved. Control
20 ticks are injected with a corresponding mixture
that does not contain the active ingredient.
After this treatment, the ticks are kept in
an insectarium under normal conditions at about
28°C and 80 % relative humidity until oviposition

25

26026

has taken place and the larvae have emerged from the eggs of the control ticks.

The activity of a tested substance is determined by the IR_{90} , i.e. that dose of active ingredient is determined at which 9 out of 10 female ticks (90%), even after 30 days, lay eggs from which larvae are unable to emerge. Compounds from the Preparation Examples achieve an IR_{90} of 1 ug.

10

B-3: Trial with sheep infected with nematodes (Haemonchus contortus and Trichostrongylus colubriformis)

15

The active ingredient is formulated as a suspension and administered using a stomach probe or by intraruminal injection to sheep that have been artificially infected with Haemonchus contortus and Trichostrongylus colubriformis. 1 to 3 animals are used for each dose. Each sheep is treated only once with a single dose of, as desired, 0.5 mg or 0.1 mg/kg of body weight. Evaluation is made by comparing the number of worm eggs

25

26026

excreted in the faeces of the sheep before and after treatment.

Sheep infected simultaneously and in the same manner but untreated are used as controls. In comparison with untreated but infected control groups, nematode infestation was reduced by from 50 to 100% (= reduction of worm eggs in the faeces) in sheep that had been treated with 0.1 mg/kg of one of the compounds from the Preparation Exmaples, such as, for example, No. 1.14, 1.18, 2.14 or 5.5.

B-4: Larvicidal action against Aedes aegypti

A 0.1% solution of the active ingredient in acetone is pipetted onto the surface of 150 ml of water in containers in amounts sufficient to give concentrations of, as desired, 10 ppm, 3.3 ppm and 1.6 ppm. After the acetone has evaporated, about 30 to 40 three-day-old Aedes larvae are put into each container. Mortality counts are made after 1, 2 and 5 days.

In this test, compounds from Tables 1 to 6 at a concentration of 10 ppm achieve complete

25

26026

kill of all larvae after only 1 day.

B-5: Miticidal action against Sermanyssus
gallinae

5

2 to 3 ml of a test solution (100, 10,
1 and 0.1 ppm of active substance) are put into
a glass container which is open at the top and
about 200 mites in different stages of deve-
10 lopment are put into this container. The glass
container is sealed with a wad of cotton wool
and is uniformly shaken for 10 minutes until the
mites are completely wet. The container is then
inverted until excess test solution has been
15 absorbed by the cotton wool. The container
is then stood upright again and the treated mites
are kept under observation for 3 days under
laboratory conditions to evaluate the effective-
ness of the test substances. Mortality is the
20 criterion for effectiveness.

20


Compounds from the Preparation Examples,
such as, for example, Nos. 1.14, 1.18 and 5.5,
exhibit 100% effectiveness at 100 ppm.

25

260 26

Patent Claims

1. Compounds of formula I



in which

A is a $\begin{matrix} -\text{CH}- \\ | \\ \text{OR}_1 \end{matrix}$, $\begin{matrix} -\text{C}- \\ || \\ \text{O} \end{matrix}$ or $\begin{matrix} -\text{C}- \\ || \\ \text{N}-\text{OR}_{11} \end{matrix}$ group

wherein R₁ is hydrogen or an OH-protecting group,
and R₁₁ is hydrogen or an OH-protecting group,

BAD ORIGINAL 

26028

R_2 is methyl, ethyl, isopropyl or sec-butyl,
 R_3 and R_4 together represent a bond between the two
carbon atoms to which they are bound, or together
represent a $-C(X')(Z')-$ group wherein X' and
 Z' each represents, independently of the other,
hydrogen or halogen, and
 X and Z each represents, independently of the other,
hydrogen or halogen.

2. Compounds of formula I according to claim 1, wherein
 A is any one of the groups $-CH(OR_1)-$, $-C(O)-$ or
 $-C(=N-OH)-$ wherein R_1 is hydrogen, a silyl group
or a mono-saccharide group, R_2 is methyl or ethyl,
 R_3 and R_4 together form a bond between the two carbon
atoms to which they are bound, or together form a
 $-C(X')(Z')-$ group wherein X' and Z' each represents,
independently of the other, hydrogen or halogen, and
 X and Z each represents, independently of the other,
hydrogen or halogen.

3. Compounds of formula I according to claim 1, wherein
 A is any one of the groups $-CH(OR)_1-$, $-C(O)-$ or
 $-C(=N-OH)-$ wherein R_1 is hydrogen, acetyl, tert.-
butyldimethylsilyl or 2, 3, 4, 6-tetraacetylglucopyranosyl,



26026

R_2 is methyl or ethyl, R_3 and R_4 together form a bond between the two carbon atoms to which they are bound, or together form a $-C(Cl_2)-$ group, X is hydrogen, chlorine, bromine or fluorine, and Z is hydrogen, chlorine, bromine or fluorine.

4. Compounds of formula I according to claim 1, wherein A is any one of the groups $-CH(OR_1)-$, $-C(O)-$ or $-C(=N-OH)-$ wherein R_1 is hydrogen, tert.-butyl-dimethylsilyl or 2, 3, 4, 6-tetraacetylglucopyranosyl, R_2 is methyl or ethyl, R_3 and R_4 together form a bond between the two carbon atoms to which they are bound, or together form a $-C(Cl_2)-$ group, X is hydrogen, chlorine or bromine and Z is hydrogen, chlorine or bromine.

5. Compounds of formula I according to claim 1, wherein A is a $-CH(OH)-$ or $-C(=N-OH)-$ group, R_2 is methyl or ethyl, R_3 and R_4 together form a bond between the two carbon atoms to which they are bound, X is hydrogen, chlorine, bromine or fluorine, and Z is hydrogen, chlorine, bromine or fluorine.



26026

6. Compounds of formula I according to claim 1, wherein A is a $-\text{CH}(\text{OH})-$ or $-\text{C}(=\text{N}-\text{OH})-$ group, R_2 is methyl or ethyl, R_3 and R_4 together form a bond between the two carbon atoms to which they are bound, and X and Z are identical with each other and each represents hydrogen, chlorine or bromine, or X is hydrogen and Z is chlorine or bromine.

7. Compounds of formula I according to claim 1, wherein A is a $-\text{CH}(\text{OH})-$ group, R_2 is methyl or ethyl, R_3 and R_4 together form a bond between the two carbon atoms to which they are bound, or together form a $-\text{CCl}_2-$ group, X is hydrogen, chlorine or bromine, and Z is hydrogen, chlorine or bromine.

8. 5-O-(Tert.-butyldimethylsilyl)-14, 15-dichloromethylene-14, 15-dihydromilbemycin A_4 .


9. 5-O-(Tert.-butyldimethylsilyl)-3, 4-dichloromethylene-14, 15-dichloromethylene-3, 4, 14, 15-tetrahydromilbemycin A_4 .

26026

10. 3, 4-Dichloromethylene-14, 15-dichloromethylene-3, 4, 14, 15-tetrahydromilbemycin A₄.
11. 5-O-(Tert.-butyldimethylsilyl)-14, 15-dibromomethylene-14, 15-dihydromilbemycin A₄.
12. 5-O-(2, 3, 4, 6-Tetraacetylglucopyranosyl)-14, 15-dichloromethylene-14, 15-dihydromilbemycin A₄.
13. 5-Oxo-14, 15-dichloromethylene-14, 15-dihydromilbemycin A₄.
14. 5-Hydroxyimino-14, 15-dichloromethylene-14, 15-dihydromilbemycin A₄.
15. 14, 15-Dichloromethylene-14, 15-dihydromilbemycin A₄.
16. 5-O-(Tert.-butyldimethylsilyl)-14, 15-monobromomethylene-14, 15-dihydromilbemycin A₄.
17. 14, 15-Monobromomethylene-14, 15-dihydromilbemycin A₄.
18. 14, 15-Monochloromethylene-14, 15-dihydromilbemycin A₄.



19. 5-O-(tert.-butyldimethylsilyl)-14, 15-methylene-14, 15-dihydromilbemycin A₄.
20. 14, 15-Methylene-14, 15-dihydromilbemycin A₄.
21. 14, 15-Dibromomethylene-14, 15-dihydromilbemycin A₄.
22. 14, 15-Dichloromethylene-14, 15-dihydromilbemycin A₄.
23. A process for the preparation of compounds of formula 1




(1)

BAD ORIGINAL




260 26

in which



wherein R_1 is hydrogen or an OH-protecting group, and R_{11} is hydrogen or an OH-protecting group, R_2 is methyl, ethyl, isopropyl or sec.-butyl, R_3 and R_4 together represent a bond between the two carbon atoms to which they are bound, or together represent a $-\text{C}(\text{X}')(\text{Z}')-$ group wherein X' and Z' each represents, independently of the other hydrogen or halogen, and X and Z each represents, independently of the other hydrogen, wherein a compound of formula II



BAD ORIGINAL

26026

in which A and R₂ are as defined for formula I, is reacted with a carbene of formula IIIa



in which X and Z are as defined for formula I and which is formed in situ and is dissolved in an inert solvent, and, in resulting compounds, if desired i) a -C(halogen)(halogen)- group that represents -C(X)(Z)- is reduced to a -CH(halogen)- or -CH₂- group or ii) a -CH(halogen)- group that represents -C(X)(Z)- is reduced to a -CH₂- group or iii) the group that represents A is converted into another of the groups defined under A, or resulting compounds in which R₃ and R₄ together form a bond between the two carbon atoms to which they are bound are reacted with a carbene of formula IIIb



in which X' and Z' are as defined for formula I and which is formed in situ and is dissolved in an inert solvent, and, in resulting compounds, if

26026

desired iv) a $-C(\text{halogen})(\text{halogen})-$ group that represents $-C(X)(Z)-$ or $-C(X')(Z')-$ is reduced to a $-CH(\text{halogen})-$ or $-CH_2-$ group or v) a $-CH(\text{halogen})-$ group that represents $-C(X)(Z)-$ or $-C(X')(Z')-$ is reduced to a $-CH_2-$ group or vi) the group that represents A is converted into another of the groups defined under A, the reaction being carried out in the range of from -70° to $+80^\circ$ C, the reaction time varying within a range of from 10 minutes to 2 days.

24. A composition for controlling ecto- and endo-parasites in productive livestock or for controlling harmful insects, containing as active ingredient, at least one compound of formula I according to claim 1, together with carriers, distributing agents of a mixture of carriers and distributing agents.

